Abbott Laboratories stock gains 1.09% to EUR 98.95 premarket
Published on 11/11/2026 at 08:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCardiology Data Keep Focus On Pipeline
- Abbott reported one-year data for its next-generation Amulet 360 heart device, citing high rates of left atrial appendage closure and a low incidence of stroke.
- Abbott published the Amulet 360 update on November 2, 2026, adding a fresh cardiovascular development to its product pipeline.
Abbott Laboratories stock traded at 98.95 euros on Lang & Schwarz at 08:30 CET on Wednesday, November 11, 2026, 1.09 percent above the Xetra close of Tuesday, November 10, 2026 at 97.88 euros.
Abbott is also in focus after its Abbott MediaRoom listed one-year data for the next-generation Amulet 360 device on November 2. The company said the data showed high rates of left atrial appendage closure and a low incidence of stroke.
Pipeline Evidence Meets Regulatory Execution
The Amulet 360 update keeps attention on Abbott's cardiovascular device pipeline. For investors, the development adds clinical evidence to the product story, while future progress will depend on how the device advances through its development path.
The broader US market remains the relevant backdrop for Abbott stock, alongside the S&P 500.
